Paper33322239
The Molecular 'Myc-anisms' Behind Myc-Driven Tumorigenesis and the Relevant Myc-Directed Therapeutics.
McAnulty J and 1 other. Int J Mol Sci, 2020. Cited by 19 papers, by iCite.
Cite this record
ConductScience Library. The Molecular 'Myc-anisms' Behind Myc-Driven Tumorigenesis and the Relevant Myc-Directed Therapeutics. Papers, record 33322239. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33322239
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The Molecular 'Myc-anisms' Behind Myc-Driven Tumorigenesis and the Relevant Myc-Directed Therapeutics.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Cell Cycle | Major topic |
| Gene Expression Regulation, Neoplastic | Major topic |
| Molecular Targeted Therapy | Major topic |
| Neoplasms | Major topic |
| Proto-Oncogene Proteins c-myc | Major topic |
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | |
| Carcinogenesis | |
| Dimerization | |
| Humans | |
| Protein Stability | |
| Proto-Oncogene Mas | |
| Synthetic Lethal Mutations | |
| Up-Regulation |
Source PubMed
References226
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23021216 | c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. | Cell | 2012 | https://conductscience.org/library/papers/23021216 | PubMed |
| 2 | 9694806 | Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. | Genes Dev | 1998 | https://conductscience.org/library/papers/9694806 | PubMed |
| 3 | 25739120 | Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma. | Oncotarget | 2015 | https://conductscience.org/library/papers/25739120 | PubMed |
| 4 | 24444383 | Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells. | BMC Cancer | 2014 | https://conductscience.org/library/papers/24444383 | PubMed |
| 5 | 2997622 | L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. | Nature | 1985 | https://conductscience.org/library/papers/2997622 | PubMed |
| 6 | 20882107 | Myc: Maestro of MicroRNAs. | Genes Cancer | 2010 | https://conductscience.org/library/papers/20882107 | PubMed |
| 7 | 22608923 | Negative regulation of the stability and tumor suppressor function of Fbw7 by the Pin1 prolyl isomerase. | Mol Cell | 2012 | https://conductscience.org/library/papers/22608923 | PubMed |
| 8 | 1406955 | Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. | Nature | 1992 | https://conductscience.org/library/papers/1406955 | PubMed |
| 9 | 31653826 | PROTAC induced-BET protein degradation exhibits potent anti-osteosarcoma activity by triggering apoptosis. | Cell Death Dis | 2019 | https://conductscience.org/library/papers/31653826 | PubMed |
| 10 | 29471852 | CDK9 inhibitors in acute myeloid leukemia. | J Exp Clin Cancer Res | 2018 | https://conductscience.org/library/papers/29471852 | PubMed |
| 11 | 27440272 | Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model. | Clin Cancer Res | 2017 | https://conductscience.org/library/papers/27440272 | PubMed |
| 12 | 31429028 | Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma. | Target Oncol | 2019 | https://conductscience.org/library/papers/31429028 | PubMed |
| 13 | 24737842 | MYC and the art of microRNA maintenance. | Cold Spring Harb Perspect Med | 2014 | https://conductscience.org/library/papers/24737842 | PubMed |
| 14 | 30906568 | Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy. | Future Sci OA | 2019 | https://conductscience.org/library/papers/30906568 | PubMed |
| 15 | 28598431 | A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action. | Nat Commun | 2017 | https://conductscience.org/library/papers/28598431 | PubMed |
| 16 | 32260326 | Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc. | Cells | 2020 | https://conductscience.org/library/papers/32260326 | PubMed |
| 17 | 24393852 | Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer. | Clin Breast Cancer | 2014 | https://conductscience.org/library/papers/24393852 | PubMed |
| 18 | 16109377 | Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. | Mol Cell | 2005 | https://conductscience.org/library/papers/16109377 | PubMed |
| 19 | 31767764 | Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance. | Proc Natl Acad Sci U S A | 2019 | https://conductscience.org/library/papers/31767764 | PubMed |
| 20 | 28649135 | Synthetic lethality and cancer. | Nat Rev Genet | 2017 | https://conductscience.org/library/papers/28649135 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41961353 | Exploring the Molecular and Genomic Landscape of the Dark Agouti Rat Mammary Adenocarcinoma: Preliminary Insights for Triple-Negative Breast Cancer Modeling. | J Mammary Gland Biol Neoplasia | 2026 | https://conductscience.org/library/papers/41961353 | PubMed |
| 41173942 | Pan-cancer Myc modulator that targets Myc-α-tubulin interaction to drive selective mitotic catastrophe. | Sci Rep | 2025 | https://conductscience.org/library/papers/41173942 | PubMed |
| 40903666 | Targeting the TRIB3-MYC axis in cancer: mechanistic insights and therapeutic disruption strategies. | Invest New Drugs | 2025 | https://conductscience.org/library/papers/40903666 | PubMed |
| 40076599 | Untangling the Role of MYC in Sarcomas and Its Potential as a Promising Therapeutic Target. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40076599 | PubMed |
| 39873147 | Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer. | Mol Cancer Ther | 2025 | https://conductscience.org/library/papers/39873147 | PubMed |
| 38413795 | AF1q is a universal marker of neuroblastoma that sustains N-Myc expression and drives tumorigenesis. | Oncogene | 2024 | https://conductscience.org/library/papers/38413795 | PubMed |
| 38391958 | Complexity of the Genetic Background of Oncogenesis in Ovarian Cancer-Genetic Instability and Clinical Implications. | Cells | 2024 | https://conductscience.org/library/papers/38391958 | PubMed |
| 37047814 | A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37047814 | PubMed |
| 37002510 | Small molecule inhibitors for cancer metabolism: promising prospects to be explored. | J Cancer Res Clin Oncol | 2023 | https://conductscience.org/library/papers/37002510 | PubMed |
| 35099769 | IDP-410: a Novel Therapeutic Peptide that Alters N-MYC Stability and Reduces Angiogenesis and Tumor Progression in Glioblastomas. | Neurotherapeutics | 2022 | https://conductscience.org/library/papers/35099769 | PubMed |
| 34944895 | Arginine Depletion in Human Cancers. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34944895 | PubMed |
| 34631699 | Differential Expression of the TLR4 Gene in Pan-Cancer and Its Related Mechanism. | Front Cell Dev Biol | 2021 | https://conductscience.org/library/papers/34631699 | PubMed |
| 33897436 | Chemoresponse of de novo Acute Myeloid Leukemia to "7+3" Induction can Be Predicted by c-Myc-facilitated Cytogenetics. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/33897436 | PubMed |
Genes51
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33322239
GET https://conductscience.org/api/papers/v1/33322239/references?page=2